Key result
Ro-32-0432 reduces heart weight-to-body weight ratio ~23% and lowers heart failure biomarkers in experimental myocarditis.
Why the study?
Does intraperitoneal administration of the PKC inhibitor Ro-32-0432 attenuate myocardial damage, apoptosis, fibrosis, and inflammation in Lewis rats with experimental autoimmune myocarditis?
Does intraperitoneal administration of the PKC inhibitor Ro-32-0432 attenuate myocardial damage, apoptosis, fibrosis, and inflammation in Lewis rats with experimental autoimmune myocarditis?
Inhibition of PKC signaling with Ro-32-0432 attenuates heart failure biomarkers, intrinsic myocardial apoptosis, cardiac fibrosis, and IL-1beta/IL-17 expression in rat experimental autoimmune myocarditis, suggesting PKC inhibition as a potential therapeutic strategy for myocarditis.
Answers are grounded in this paper and cite their sources.
Should not yet change clinical practice; hypothesis-generating for PKC inhibition in autoimmune myocarditis.
// Chunlian Zhong 1 , Yang Wu 1, 2 , He Chang 1, 2 , Chunxiao Liu 1, 2 , Li Zhou 1 , Jun Zou 1 and Zhi Qi 1 1 Department of Basic Medical Sciences, Medical College of Xiamen University, Xiang’an Nan Lu, Xiamen, China 2 Xiamen Cardiovascular Hospital, Medical College of Xiamen University, Xiamen, China Correspondence to: Jun Zou, email: zoujun@xmu.edu.cn Zhi Qi, email: qizhi@xmu.edu.cn Keywords: myocarditis, PKC signaling, PKC inhibitor, apoptosis, inflammation Abbreviations: EAM-experimental autoimmune myocarditis, ANP-atrial natriuretic peptide, BNP-brain natriuretic peptide Received: January 02, 2017 Accepted: March 31, 2017 Published: April 10, 2017 ABSTRACT Myocarditis is a major cause of sudden, unexpected death in young people. However, it is still one of the most challenging diseases to treat in cardiology. In the present study, we showed that both expression level and activity of PKC-α were up-regulated in the rat heart of experimental autoimmune myocarditis (EAM). Intraperitoneal administration of PKC inhibitor (Ro-32-0432) at the end of the most severe inflammation period of EAM still significantly reduced the EAM induced expression of failure biomarkers. Furthermore, Ro-32-0432 reduced the ratio of Bax/Bcl-2 and suppressed the expression of cleaved caspase-3, both of which were increased in the heart of the EAM rats, suggesting an anti-apoptotic role of Ro-32-0432. Besides, Ro-32-0432 suppressed EAM-induced cardiac fibrosis and release of pro-inflammatory cytokines IL-1β and IL-17. These results suggest that inhibition of PKC may serve as a potential therapeutic strategy for the treatment of myocarditis.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2017) studied Experimental autoimmune myocarditis (EAM). Ro-32-0432 (PKC inhibitor) vs. Untreated EAM rats and control rats immunized with complete Freund's adjuvant only was evaluated on Heart weight to body weight ratio (HW/BW) at week 3 (p=<0.05). Ro-32-0432 significantly reduced the heart weight to body weight ratio from 6.2 to 4.8 and decreased heart failure biomarkers ANP and BNP in rats with experimental autoimmune myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: